Through our cross-functional teams, we provide pharmaceutical, biotechnology and medical device companies with a strategic partner that truly understands the HTA and regulatory landscape at every step of the product lifecycle.
The decisions that shape a product's commercial future are rarely made at the payer's desk; they happen earlier, in the choices around positioning, evidence priorities and market sequencing that set the trajectory long before submission. HEOR Value Hub helps clients make those choices with clarity and confidence, bringing unmet need assessment and payer expectations together into one coherent access strategy. Our approach is hands-on and partner-led, designed in particular for small and emerging biopharma where every decision has to earn its place.
We combine strategic insight with practical payer knowledge across Europe, the UK, Canada, Australia, Korea and Brazil (among other markets), with particular depth in rare diseases and highly specialised indications. These are settings where evidence is often limited and the HTA bar is high, and precisely where our structured, evidence-led approach helps clients anticipate challenges and secure favourable outcomes.
What distinguishes our support is continuity. We work alongside global and local teams from early opportunity assessment through launch readiness, payer negotiation and post-launch optimisation, closing the gap where access strategy typically fragments between headquarters and affiliates.
Economic modelling is the analytical foundation of every successful HTA submission, and one of HEOR Value Hub's deepest capabilities. Our cofounders and senior leads each bring more than a decade of hands-on experience building, defending and adapting models in complex therapeutic areas, producing analyses that are technically rigorous, strategically purposeful and built to answer the questions that actually matter to HTA bodies, payers and internal decision-makers.
We cover the full range of modelling techniques (partitioned survival, Markov, decision-tree, patient-level simulation, dynamic transmission, budget impact and cost-minimisation) across HTA environments in Europe, the UK, Canada, Australia and Brazil. Every model is supported by a structured validation framework and documentation clear enough for local teams to adapt and defend long after delivery.
Uncertainty is designed in from the start: sensitivity and scenario analyses form part of the value story, identifying what genuinely drives cost-effectiveness, quantifying the risk around key assumptions, and translating the results into defensible messages.
Every value proposition rests on the evidence behind it — how it is found, appraised, synthesised and, where needed, generated afresh. HEOR Value Hub brings senior expertise in biostatistics, epidemiology and evidence synthesis, with particular experience in small-trial and orphan-indication settings that reward careful, bespoke methodology.
Our work is grounded in international best practice — PRISMA, NICE DSU and ISPOR guidance, GRADE appraisal and transparent pre-specified analysis plans. We scope every evidence programme with payer questions firmly in mind, prioritising analyses that strengthen the value story rather than those that are simply conventional.
HEOR Value Hub's capability spans targeted and systematic literature reviews, feasibility assessment, network meta-analyses, population-adjusted indirect comparisons, statistical analysis of trial and real-world data and evidence elicitation via advisory board, Delphi panel and structured expert elicitation. We work in R and SAS, pairing statistical rigour with interpretability.
The most compelling evidence achieves nothing if it does not reach decision-makers in a form they can use. HEOR Value Hub turns complex health-economic and clinical data into communication that is clear, credible and consistent. Our communication combines senior HEOR expertise with hands-on writing experience for HTA agencies, publications and international congresses, producing materials that inform, persuade and withstand challenge.
Our work covers the full arc of scientific and value communication: from core value story and global value dossier through HTA dossiers, payer objection handlers and internal training tools, to peer-reviewed manuscripts, conference posters and podium presentations. We integrate closely with medical, market access, publications and communications teams to ensure every deliverable feels part of a single, coherent narrative.
That scientific discipline, combined with a strong sense of audience and a commitment to readability, is what makes HEOR Value Hub a dependable voice for companies whose value story needs to land with clarity and authority, wherever their product is being considered.
Supporting successful product launches across global markets with deep domain knowledge.
Specialized strategies for orphan drugs and ultra-rare conditions.
Complex evidence synthesis for breakthrough cancer therapies.
Evidence generation for cardiovascular diseases and risk management.
Navigating long-term outcomes and patient quality.
Including diabetes and metabolic syndromes.
Navigating complex pathways for autoimmune therapies.
Navigating the evolving landscape of access.
Value demonstration for advanced imaging and diagnostics.
Deep expertise in blood-related disorders.
Strategic evidence for vision-saving therapies.
Payer-focused evidence for skin conditions.
Contact our expert team today for an initial consultation on your market access strategy.
Start a Project
